Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNCOPE: Systemic neoadjuvant and adjuvant precision medicine in high-risk rectal cancer
2024-517149-15-00Phase 4Authorised
- Sponsor
- Helsinki University Hospital
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of capecitabine and oxaliplatin in rectal adenocarcinoma, sponsored by Helsinki University Hospital. Primary endpoints: Recurrence-free survival at 3 years and Recurrence-free survival at 5 years. Planned start Sep 2024; status: authorised.
02
Drugs
capecitabineoxaliplatin
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on 2024-517149-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517149-15-00.